Sectors
LBRX
LB Pharmaceuticals Inc
46.55
2 x 32.42
2 x 57.43
bid
ask
-
1.18
2.47%
02:00 PM
timesize
| Ytd | 109.12% | |
| 1y | 169.08% |
46.38
day range
47.50
13.36
52 week range
50.16
| Open | 47.47 | Prev Close | 47.73 | Low | 46.38 | High | 47.50 | Mkt Cap | 1.50B |
| Vol | 82.10K | Avg Vol | 325.77K | EPS | -5.10 | P/E | N/A | Forward P/E | -9.48 |
| Beta | N/A | Short Ratio | 13.65 | Inst. Own | 101.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 38.74 | 200-d Avg | 27.88 | 1yr Est | 53.38 |
| Income Statement | |||
| Operating Expenses | 53.92M | ||
| Research and Development Expense | 44.15M | ||
| Selling, General and Administrative Expense | 9.77M | ||
| Operating Income | -53.91M | ||
| Net Income | -51.60M | ||
| Net Income Common Stock | -51.60M | ||
| Net Income Common Stock (USD) | -51.60M | ||
| Consolidated Income | -51.60M | ||
| Earnings per Basic Share | -1.71 | ||
| Earnings per Basic Share (USD) | -1.71 | ||
| Earnings per Diluted Share | -1.71 | ||
| Earning Before Interest & Taxes (EBIT) | -51.60M | ||
| Earning Before Interest & Taxes (USD) | -51.60M | ||
| Weighted Average Shares | 30.14M | ||
| Weighted Average Shares Diluted | 30.14M | ||
| Balance Sheet | |||
| Cash and Equivalents | 283.89M | ||
| Cash and Equivalents (USD) | 283.89M | ||
| Investments | 44.68M | ||
| Investments Current | 44.68M | ||
| Current Assets | 355.30M | ||
| Property, Plant & Equipment Net | 5.61M | ||
| Total Assets | 361.69M | ||
| Debt Current | 844.00K | ||
| Total Debt | 5.22M | ||
| Current Liabilities | 23.56M | ||
| Debt Non-Current | 4.37M | ||
| Total Liabilities | 29.35M | ||
| Accumulated Retained Earnings (Deficit) | -200.18M | ||
| Accumulated Other Comprehensive Income | 186.00K | ||
| Shareholders Equity | 332.35M | ||
| Shareholders Equity (USD) | 332.35M | ||
| Assets Non-Current | 6.39M | ||
| Total Debt (USD) | 5.22M | ||
| Liabilities Non-Current | 5.78M | ||
| Trade and Non-Trade Payables | 3.49M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 190.00K | ||
| Net Cash Flow from Financing | -19.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -37.56M | ||
| Capital Expenditure | -363.00K | ||
| Issuance (Purchase) of Equity Shares | -19.00K | ||
| Net Cash Flow from Investing | 89.00K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 452.00K | ||
| Net Cash Flow from Operations | -37.63M | ||
| Share Based Compensation | 4.90M | ||